Abstract
Background Initiation and progression of Angioimmunoblastic T cell lymphoma (AITL) and peripheral T cell lymphoma, not otherwise specified (PTCL-NOS), remains poorly understood. A subset of AITL/PTCL-NOS patients develop concomitant hematologic neoplasms (CHN), including myeloid and B-cell neoplasms, and a biomarker to predict this risk is lacking. We explore these unknown areas by exploring potential relationship among clonal hematopoiesis (CH), AITL/PTCL-NOS and CHN using a genomics approach.
Methods We performed a retrospective study of patients with AITL (n=25) or PTCL-NOS (n=2) whose lymphoma and matched bone marrow (BM) or peripheral blood (PB) specimens were collected and subjected to targeted next-generation sequencing. Clinicopathologic data of these cases were retrieved from the medical records. CH-associated and lymphoma-specific mutations were identified, analyzed and compared among T-cell lymphoma, CH in BM/PB, and if present, CHN.
Findings 70.4% of the AITL/PTCL-NOS patients were found to harbor CH-associated genomic alterations, characterized by loss-of-function mutations in TET2 and DNMT3A. The CH-associated alterations were shared among CH and T cell lymphoma, as well as concurrent myeloid neoplasms or diffuse large B-cell lymphoma (DLBC) that occurred before or after AITL development. Mutations acquired at a later stage of AITL/PTCL-NOS development were enriched for tobacco smoking-associated missense mutations. Kaplan-Meier survival analysis showed that the presence of ≥2 CH-associated TET2 mutations with ≥ 15% allele burden was associated with significantly higher risk for CHN (hazard ratio = 10.81, CI 2.2 to 53.16, p value = 0.0022, PPV = 87.5%, NPV = 92.7%).
Interpretation We provided genetic evidence that AITL/PTCL-NOS, CH, myeloid neoplasms and even DLBCL can frequently arise from common mutated hematopoietic stem-cell clones. Our findings also support smoking exposure as a potential risk factor for AITL/PTCL-NOS development, and identify potential biomarker for CHN risk in AITL/PTCL-NOS patients.
Funding the National Cancer Institute.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study is supported by a grant (R01 CA194547) from the National Cancer Institute to Dr. Wayne Tam.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
the Institutional Review Board of Weill Cornell Medicine, New York, USA
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data referred to in the manuscript are provided or available upon request.